Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: A prospective, randomised study comparing two doses of parnaparin (BAFLUX STUDY)

References 

1. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176–2183
2. DeMaria EJ, Murr M, Byrne TK, Blackstone R, Grant JP, Budak A, et al. Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity. Ann Surg. 2007;246:578–582
3. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–2693
4. Prystowsky JB, Morasch MD, Eskandari MK, Hungness ES, Nagle AP. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. Surgery. 2005;138:759–763
   • Abstract
   • Full Text
   • Full-Text PDF (91 KB)
5. Podnos YD, Jimenez JC, Wilson SE, Stevens CM, Nguyen NT. Complications after laparoscopic gastric bypass: a review of 3464 cases. Arch Surg. 2003;138:957–961
   • MEDLINE
6. Rocha AT, de Vasconcellos AG, da Luz Neto ER, Araújo DM, Alves ES, Lopes AA. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg. 2006;16:1645–1655
   • MEDLINE
7. Westling A, Bergqvist D, Boström A, Karacagil S, Gustavsson S. Incidence of deep venous thrombosis in patients undergoing obesity surgery. World J Surg. 2002;26:470–473
   • MEDLINE
8. Gonzalez QH, Tishler DS, Plata-Munoz JJ, Bondora A, Vickers SM, Leath T, et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2004;18:1082–1084
9. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12:19–24
   • MEDLINE
10. Kalfarentzos F, Stavropoulou F, Yarmenitis S, Kehagias I, Karamesini M, Dimitrakopoulos A, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. Obes Surg. 2001;11:670–676
    • MEDLINE
11. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE study). Obes Surg 2005;15:1368–7.
12. Kothari SN, Lambert PJ, Mathiason MA. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. Am J Surg. 2007;194:709–711
    • Abstract
    • Full Text
    • Full-Text PDF (44 KB)
13. Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg. 2000;10:7–13
    • MEDLINE
14. Seddighzadeh A, Zurawska U, Shetty R, Goldhaber SZ. Venous thromboembolism in patients undergoing surgery: low rates of prophylaxis and high rates of filter insertion. Thromb Haemost. 2007;98:1220–1225
15. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol. 2000;56:293–297
    • MEDLINE
16. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26:24–38
17. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308–318
    • MEDLINE
18. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87:817–823
    • MEDLINE
19. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:188 S–203S
20. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of Venous Thromboembolism. American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S–453S.
21. Desjardins L, Bara L, Boutitie F, Samama MM, Cohen AT, Combe S, et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med. 2004;128:519–526
22. O'Connell MP, O'Leary M, MacKeogh L, Murphy K, Keane DP. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?. Eur J Obstet Gynecol Reprod Biol. 2004;114:12–14
    • Abstract
    • Full Text
    • Full-Text PDF (65 KB)
23. Rutherford EJ, Schooler WG, Sredzienski E, Abrams JE, Skeete DA. Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma. 2005;58:1167–1170
    • MEDLINE
24. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving low molecular weight heparin enoxaparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989;62:940–944
    • MEDLINE
25. McKeage K, Keating GM. Parnaparin: a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs. 2008;68:105–122
26. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet. 2004;364:911–912
    • Abstract
    • Full Text
    • Full-Text PDF (169 KB)
27. Legnani C, Imberti D, Cini M, Dedola D, Baldini E, Della Valle E, et al. Pharmacodynamic of low molecular weight heparin (LMWH) in obese subjects undergoing bariatric surgery: a prospective randomised study comparing two different doses of parnaparin. Haematologica. 2006;91:89;[abs]
28. Forestieri P, Quarto G, De Caterina M, Cuocolo A, Pilone V, Formato A, et al. Prophylaxis of thromboembolism in bariatric surgery with parnaparin. Obes Surg. 2007;17:1558–1562
29. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31:42–48
    • MEDLINE
30. Heinzmann M, Baerlocher GM, Steinmann F, Horber FF, Wuillemin W. Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis. Thromb Res. 2002;106:179–181
    • Abstract
    • Full Text
    • Full-Text PDF (86 KB)
31. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107–112
    • MEDLINE
32. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254